{"transactions":[{"id":3855503,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2018-08-02T16:19:53.000Z","date":"2018-08-01","kind":"grant","acquired":true,"shares":27900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 57,315 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 07/09/2018, under which one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date."}],"balance_after":378228,"source":{"system":"sec-edgar","filing":"0001140361-18-035141","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036118035141/doc1.xml","form_type":"4"}},{"id":3869620,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2018-07-11T17:35:30.000Z","date":"2018-07-09","kind":"grant","acquired":true,"shares":57315,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 57,315 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 07/09/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date."}],"balance_after":350328,"source":{"system":"sec-edgar","filing":"0001140361-18-032187","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036118032187/doc1.xml","form_type":"4"}},{"id":4021363,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-02T17:27:44.000Z","date":"2017-06-28","kind":"grant","acquired":true,"shares":35000,"price":10.51,"value":367850.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Options become exercisable as to all 35,000 ADSs on the first anniversary of the 06/28/2017 grant date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Options become exercisable as to all 35,000 ADSs on the first anniversary of the 06/28/2017 grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options become exercisable as to all 35,000 ADSs on the first anniversary of the 06/28/2017 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":35000,"derivative":{"exercise_price":10.51,"exercise_date":"2018-06-28","expiration_date":"2022-06-28","underlying":"ADSs","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001140361-18-011731","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036118011731/doc1.xml","form_type":"4/A","original_submission_date":"2017-06-30"}},{"id":4127142,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-12-19T19:47:31.000Z","date":"2017-12-15","kind":"purchase","acquired":true,"shares":70000,"price":8.671,"value":606970.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.45 to $8.75, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":180000,"source":{"system":"sec-edgar","filing":"0001140361-17-046810","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117046810/doc1.xml","form_type":"4/A","original_submission_date":"2017-12-19"}},{"id":4127141,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-12-19T19:47:31.000Z","date":"2017-12-15","kind":"purchase","acquired":true,"shares":70000,"price":8.671,"value":606970.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.45 to $8.75, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2)."}],"balance_after":323413,"source":{"system":"sec-edgar","filing":"0001140361-17-046810","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117046810/doc1.xml","form_type":"4/A","original_submission_date":"2017-12-19"}},{"id":4127140,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-12-19T16:09:34.000Z","date":"2017-12-15","kind":"grant","acquired":true,"shares":70000,"price":8.671,"value":606970.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.45 to $8.75, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":180000,"source":{"system":"sec-edgar","filing":"0001140361-17-046734","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117046734/doc1.xml","form_type":"4"}},{"id":4127139,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-12-19T16:09:34.000Z","date":"2017-12-15","kind":"grant","acquired":true,"shares":70000,"price":8.671,"value":606970.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.45 to $8.75, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2)."}],"balance_after":323413,"source":{"system":"sec-edgar","filing":"0001140361-17-046734","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117046734/doc1.xml","form_type":"4"}},{"id":4149441,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-11-29T16:35:20.000Z","date":"2017-11-27","kind":"sale","acquired":false,"shares":254265,"price":9.351,"value":2377632.015,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the transfer of ADSs of the issuer by the reporting person to a trust of which the trustees are two adult children of the reporting person who do not live in the reporting person's household.  In consideration for the transfer of these ADSs, the trust gave the reporting person property with an aggregate value approximately equal to the market value of the transferred ADSs on the date of the transfer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the transfer of ADSs of the issuer by the reporting person to a trust of which the trustees are two adult children of the reporting person who do not live in the reporting person's household.  In consideration for the transfer of these ADSs, the trust gave the reporting person property with an aggregate value approximately equal to the market value of the transferred ADSs on the date of the transfer."}],"balance_after":253413,"source":{"system":"sec-edgar","filing":"0001140361-17-044178","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117044178/doc1.xml","form_type":"4"}},{"id":4209680,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-09-14T17:06:06.000Z","date":"2017-09-12","kind":"purchase","acquired":true,"shares":20000,"price":9.518,"value":190360.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.14 to $9.84, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":110000,"source":{"system":"sec-edgar","filing":"0001140361-17-035546","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117035546/doc1.xml","form_type":"4"}},{"id":4269579,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-30T16:20:43.000Z","date":"2017-06-28","kind":"grant","acquired":true,"shares":30000,"price":10.51,"value":315300.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Options become exercisable as to all 30,000 ADSs on the first anniversary of the 06/28/2017 grant date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Options become exercisable as to all 30,000 ADSs on the first anniversary of the 06/28/2017 grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Options become exercisable as to all 30,000 ADSs on the first anniversary of the 06/28/2017 grant date."}],"balance_after":30000,"derivative":{"exercise_price":10.51,"exercise_date":"2018-06-28","expiration_date":"2022-06-28","underlying":"ADSs","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-17-026870","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117026870/doc1.xml","form_type":"4"}},{"id":4279536,"issuer":{"id":3771,"kind":"organization","name":"ABERCROMBIE & FITCH CO /DE/","symbol":"ANF"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2017-06-16T20:12:33.000Z","date":"2017-06-15","kind":"exercise","acquired":false,"shares":8043,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"This award converts to Common Stock of the Issuer on a 1-for-1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Vests the earlier of the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Vests the earlier of the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders."}],"balance_after":0,"derivative":{"exercise_date":"2017-06-16","underlying":"Class A Common Stock","underlying_shares":8043},"source":{"system":"sec-edgar","filing":"0001225208-17-011423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1018840/000122520817011423/doc4.xml","form_type":"4"}},{"id":4279535,"issuer":{"id":3771,"kind":"organization","name":"ABERCROMBIE & FITCH CO /DE/","symbol":"ANF"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true}}],"security":"Phantom Stock","published_at":"2017-06-16T20:12:33.000Z","date":"2017-06-15","kind":"exercise","acquired":true,"shares":8043,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of phantom stock represents a right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of phantom stock become payable in the form of Common Stock of the Issuer upon the reporting person's termination of service as a director."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of phantom stock become payable in the form of Common Stock of the Issuer upon the reporting person's termination of service as a director."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Total includes accrued dividends."}],"balance_after":32660,"derivative":{"underlying":"Class A Common Stock","underlying_shares":8043},"source":{"system":"sec-edgar","filing":"0001225208-17-011423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1018840/000122520817011423/doc4.xml","form_type":"4"}},{"id":4310475,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-05-22T18:17:05.000Z","date":"2017-05-22","kind":"purchase","acquired":true,"shares":16900,"price":9.76,"value":164944.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.66 to $10.00, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001140361-17-021794","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117021794/doc1.xml","form_type":"4"}},{"id":4310474,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-05-22T18:17:05.000Z","date":"2017-05-19","kind":"purchase","acquired":true,"shares":3100,"price":9.83,"value":30473.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.75 to $9.89, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (4)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":73100,"source":{"system":"sec-edgar","filing":"0001140361-17-021794","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117021794/doc1.xml","form_type":"4"}},{"id":4310473,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-05-22T18:17:05.000Z","date":"2017-05-18","kind":"purchase","acquired":true,"shares":11013,"price":9.98,"value":109909.74,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.78 to $10.00, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0001140361-17-021794","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117021794/doc1.xml","form_type":"4"}},{"id":4314162,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-05-18T16:43:42.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":12100,"price":9.9498,"value":120392.58,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.88 to $10.00, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (4)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":58987,"source":{"system":"sec-edgar","filing":"0001140361-17-021376","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117021376/doc1.xml","form_type":"4"}},{"id":4314161,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-05-18T16:43:42.000Z","date":"2017-05-16","kind":"grant","acquired":true,"shares":3470,"price":10,"value":34700.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.99 to $10.00, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":46887,"source":{"system":"sec-edgar","filing":"0001140361-17-021376","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117021376/doc1.xml","form_type":"4"}},{"id":4319044,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-05-16T16:20:33.000Z","date":"2017-05-15","kind":"grant","acquired":true,"shares":311,"price":10,"value":3110.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.99 to $10.00, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":43417,"source":{"system":"sec-edgar","filing":"0001140361-17-020996","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117020996/doc1.xml","form_type":"4"}},{"id":4319043,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-05-16T16:20:33.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":3106,"price":10,"value":31060.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":43106,"source":{"system":"sec-edgar","filing":"0001140361-17-020996","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117020996/doc1.xml","form_type":"4"}},{"id":4358913,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-04-05T18:52:09.000Z","date":"2017-04-04","kind":"grant","acquired":true,"shares":15000,"price":9.5762,"value":143643.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.54 to $9.69, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2)."}],"balance_after":507678,"source":{"system":"sec-edgar","filing":"0001140361-17-015039","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117015039/doc1.xml","form_type":"4"}},{"id":4425419,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2017-02-24T16:47:45.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":117449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Warrants were granted 08/10/2016 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro) 12.16 per ADS. Warrants as to all 117,449 ADSs vest on 08/10/2017."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Warrants were granted 08/10/2016 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro) 12.16 per ADS. Warrants as to all 117,449 ADSs vest on 08/10/2017."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Warrants were granted 08/10/2016 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro) 12.16 per ADS. Warrants as to all 117,449 ADSs vest on 08/10/2017."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":117449,"derivative":{"exercise_price":13.59,"exercise_date":"2017-08-10","expiration_date":"2020-08-10","underlying":"ADSs","underlying_shares":117449},"source":{"system":"sec-edgar","filing":"0001140361-17-009173","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117009173/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-03"}},{"id":4425418,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2017-02-24T16:47:45.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":117449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Warrants were granted 06/26/2015 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 117,449 ADSs vested on 06/26/2016."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Warrants were granted 06/26/2015 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 117,449 ADSs vested on 06/26/2016."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Warrants were granted 06/26/2015 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 117,449 ADSs vested on 06/26/2016."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":117449,"derivative":{"exercise_price":14.54,"exercise_date":"2016-06-26","expiration_date":"2019-06-26","underlying":"ADSs","underlying_shares":117449},"source":{"system":"sec-edgar","filing":"0001140361-17-009173","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117009173/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-03"}},{"id":4425417,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2017-02-24T16:47:45.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":100000,"derivative":{"exercise_price":14.54,"exercise_date":"2015-06-24","expiration_date":"2018-06-24","underlying":"ADSs","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001140361-17-009173","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117009173/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-03"}},{"id":4425416,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-02-24T16:47:45.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":16200,"source":{"system":"sec-edgar","filing":"0001140361-17-009173","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117009173/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-03"}},{"id":4425415,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-02-24T16:47:45.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001140361-17-009173","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117009173/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-03"}},{"id":4425414,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-02-24T16:47:45.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":492678,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."}],"balance_after":492678,"source":{"system":"sec-edgar","filing":"0001140361-17-009173","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117009173/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-03"}},{"id":4491367,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2017-01-13T16:41:20.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":117449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Warrants were granted 06/26/2015 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 117,449 ADSs vest on 06/26/2016."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Warrants were granted 06/26/2015 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 117,449 ADSs vest on 06/26/2016."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Warrants were granted 06/26/2015 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 117,449 ADSs vest on 06/26/2016."}],"balance_after":117449,"derivative":{"exercise_price":14.54,"exercise_date":"2016-06-26","expiration_date":"2019-06-26","underlying":"ADSs","underlying_shares":117449},"source":{"system":"sec-edgar","filing":"0001140361-17-001887","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117001887/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-03"}},{"id":4491366,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2017-01-13T16:41:20.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS."}],"balance_after":100000,"derivative":{"exercise_price":14.54,"exercise_date":"2015-06-24","expiration_date":"2018-06-24","underlying":"ADSs","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001140361-17-001887","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117001887/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-03"}},{"id":4491365,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-01-13T16:41:20.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":16200,"source":{"system":"sec-edgar","filing":"0001140361-17-001887","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117001887/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-03"}},{"id":4491364,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-01-13T16:41:20.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001140361-17-001887","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117001887/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-03"}},{"id":4491363,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-01-13T16:41:20.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":492678,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."}],"balance_after":492678,"source":{"system":"sec-edgar","filing":"0001140361-17-001887","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117001887/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-03"}},{"id":4508566,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2017-01-03T19:21:45.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":117449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Warrants were granted 06/26/2015 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 117,449 ADSs vest on 06/26/2016."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Warrants were granted 06/26/2015 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 117,449 ADSs vest on 06/26/2016."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Warrants were granted 06/26/2015 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 117,449 ADSs vest on 06/26/2016."}],"balance_after":117449,"derivative":{"exercise_price":14.54,"exercise_date":"2016-06-26","expiration_date":"2019-06-26","underlying":"ADSs","underlying_shares":117449},"source":{"system":"sec-edgar","filing":"0001144204-17-000349","document":"v455905_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114420417000349/v455905_4.xml","form_type":"4"}},{"id":4508565,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2017-01-03T19:21:45.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS."}],"balance_after":100000,"derivative":{"exercise_price":14.54,"exercise_date":"2015-06-24","expiration_date":"2018-06-24","underlying":"ADSs","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001144204-17-000349","document":"v455905_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114420417000349/v455905_4.xml","form_type":"4"}},{"id":4508564,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-01-03T19:21:45.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":16200,"source":{"system":"sec-edgar","filing":"0001144204-17-000349","document":"v455905_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114420417000349/v455905_4.xml","form_type":"4"}},{"id":4508563,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-01-03T19:21:45.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001144204-17-000349","document":"v455905_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114420417000349/v455905_4.xml","form_type":"4"}},{"id":4508562,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-01-03T19:21:45.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":492678,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."}],"balance_after":492678,"source":{"system":"sec-edgar","filing":"0001144204-17-000349","document":"v455905_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114420417000349/v455905_4.xml","form_type":"4"}},{"id":4508481,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2017-01-03T14:45:43.000Z","date":"2016-12-31","kind":"disposition_to_issuer","acquired":false,"shares":117449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Warrants were granted 06/26/2015 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 117,449 ADSs vest on 06/26/2016."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Warrants were granted 06/26/2015 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 117,449 ADSs vest on 06/26/2016."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person is filing this Form 4 solely to report dispositions of Flamel securities as a result of the Merger. The reporting person will also file a Form 3 to reflect his or her new status as a director and/or executive officer of Avadel, and a new Form 4 evidencing his or her acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in this Form 4 or the acquisitions to be reported in the new Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Warrants were granted 06/26/2015 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 117,449 ADSs vest on 06/26/2016."}],"balance_after":0,"derivative":{"exercise_price":14.54,"exercise_date":"2016-06-24","expiration_date":"2018-06-24","underlying":"ADSs","underlying_shares":117449},"source":{"system":"sec-edgar","filing":"0001144204-17-000129","document":"v455604_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114420417000129/v455604_form4.xml","form_type":"4"}},{"id":4508480,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2017-01-03T14:45:43.000Z","date":"2016-12-31","kind":"disposition_to_issuer","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person is filing this Form 4 solely to report dispositions of Flamel securities as a result of the Merger. The reporting person will also file a Form 3 to reflect his or her new status as a director and/or executive officer of Avadel, and a new Form 4 evidencing his or her acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in this Form 4 or the acquisitions to be reported in the new Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS."}],"balance_after":0,"derivative":{"exercise_price":14.54,"exercise_date":"2015-06-24","expiration_date":"2018-06-24","underlying":"ADSs","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001144204-17-000129","document":"v455604_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114420417000129/v455604_form4.xml","form_type":"4"}},{"id":4508479,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-01-03T14:45:43.000Z","date":"2016-12-31","kind":"disposition_to_issuer","acquired":false,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person is filing this Form 4 solely to report dispositions of Flamel securities as a result of the Merger. The reporting person will also file a Form 3 to reflect his or her new status as a director and/or executive officer of Avadel, and a new Form 4 evidencing his or her acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in this Form 4 or the acquisitions to be reported in the new Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001144204-17-000129","document":"v455604_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114420417000129/v455604_form4.xml","form_type":"4"}},{"id":4508478,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-01-03T14:45:43.000Z","date":"2016-12-31","kind":"disposition_to_issuer","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person is filing this Form 4 solely to report dispositions of Flamel securities as a result of the Merger. The reporting person will also file a Form 3 to reflect his or her new status as a director and/or executive officer of Avadel, and a new Form 4 evidencing his or her acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in this Form 4 or the acquisitions to be reported in the new Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001144204-17-000129","document":"v455604_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114420417000129/v455604_form4.xml","form_type":"4"}},{"id":4508477,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2017-01-03T14:45:43.000Z","date":"2016-12-31","kind":"disposition_to_issuer","acquired":false,"shares":492678,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On 12/31/16, Flamel Technologies S.A. (\"Flamel\") merged with and into Avadel Pharmaceuticals plc (\"Avadel\"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person is filing this Form 4 solely to report dispositions of Flamel securities as a result of the Merger. The reporting person will also file a Form 3 to reflect his or her new status as a director and/or executive officer of Avadel, and a new Form 4 evidencing his or her acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in this Form 4 or the acquisitions to be reported in the new Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001144204-17-000129","document":"v455604_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114420417000129/v455604_form4.xml","form_type":"4"}},{"id":4515748,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2016-12-20T16:05:46.000Z","date":"2016-12-19","kind":"gift","acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F9","text":"Reflects the acquisition by a family trust of securities transferred from the reporting person and his spouse."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":16200,"source":{"system":"sec-edgar","filing":"0001140361-16-090366","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036116090366/doc1.xml","form_type":"4"}},{"id":4515747,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2016-12-20T16:05:46.000Z","date":"2016-12-19","kind":"gift","acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F8","text":"Reflects the acquisition by the reporting person's spouse of securities transferred from the reporting person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001140361-16-090366","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036116090366/doc1.xml","form_type":"4"}},{"id":4515746,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2016-12-20T16:05:46.000Z","date":"2016-12-19","kind":"gift","acquired":false,"shares":8100,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F7","text":"Reflects the transfer of securities by the reporting person's spouse to a family trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":26500,"source":{"system":"sec-edgar","filing":"0001140361-16-090366","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036116090366/doc1.xml","form_type":"4"}},{"id":4515745,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2016-12-20T16:05:46.000Z","date":"2016-12-19","kind":"gift","acquired":false,"shares":5400,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the transfer of securities by the reporting person's spouse to children of the reporting person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":34600,"source":{"system":"sec-edgar","filing":"0001140361-16-090366","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036116090366/doc1.xml","form_type":"4"}},{"id":4515744,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2016-12-20T16:05:46.000Z","date":"2016-12-19","kind":"gift","acquired":false,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects the transfer of securities by the reporting person to his spouse."}],"balance_after":492678,"source":{"system":"sec-edgar","filing":"0001140361-16-090366","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036116090366/doc1.xml","form_type":"4"}},{"id":4515743,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2016-12-20T16:05:46.000Z","date":"2016-12-19","kind":"gift","acquired":false,"shares":8100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects the transfer of securities by the reporting person to a family trust."}],"balance_after":506178,"source":{"system":"sec-edgar","filing":"0001140361-16-090366","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036116090366/doc1.xml","form_type":"4"}},{"id":4515742,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2016-12-20T16:05:46.000Z","date":"2016-12-19","kind":"gift","acquired":false,"shares":5400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the transfer of securities by the reporting person to his children."}],"balance_after":514278,"source":{"system":"sec-edgar","filing":"0001140361-16-090366","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036116090366/doc1.xml","form_type":"4"}},{"id":4539131,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2016-11-30T16:18:08.000Z","date":"2016-11-29","kind":"purchase","acquired":true,"shares":10000,"price":10.85,"value":108500.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001140361-16-088251","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036116088251/doc1.xml","form_type":"4"}},{"id":4539130,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2016-11-30T16:18:08.000Z","date":"2016-11-28","kind":"purchase","acquired":true,"shares":10000,"price":10.737,"value":107370.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.69 to $10.75, inclusive. The reporting person undertakes to provide to Flamel Technologies S.A., any security holder of Flamel Technologies S.A., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001140361-16-088251","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036116088251/doc1.xml","form_type":"4"}},{"id":4611736,"issuer":{"id":3771,"kind":"organization","name":"ABERCROMBIE & FITCH CO /DE/","symbol":"ANF"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true}}],"security":"Class A Common Stock","published_at":"2016-09-06T22:49:06.000Z","date":"2016-09-01","kind":"purchase","acquired":true,"shares":10000,"price":17.65,"value":176500.0,"ownership":{"direct":true},"balance_after":57398,"source":{"system":"sec-edgar","filing":"0001225208-16-038875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1018840/000122520816038875/doc4.xml","form_type":"4"}},{"id":4611765,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":157732,"kind":"person","name":"STAPLETON CRAIG R","position":1,"cik":"0001207106","reported_name":"STAPLETON CRAIG R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"ADSs","published_at":"2016-09-06T17:27:56.000Z","date":"2016-09-01","kind":"purchase","acquired":true,"shares":10000,"price":13.519,"value":135190.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.35 to $13.75, inclusive. The reporting person undertakes to provide to Flamel Technologies S.A., any security holder of Flamel Technologies S.A., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2)."}],"balance_after":519678,"source":{"system":"sec-edgar","filing":"0001144204-16-122915","document":"v448400_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114420416122915/v448400_4.xml","form_type":"4"}}]}